Eledon Pharmaceuticals to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022

Rhea-AI Summary

Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) plans to release its financial results for Q2 2022 on August 11, after market close. Management will host a conference call and webcast at 4:30 pm ET to discuss these results. Eledon specializes in developing treatments for organ transplantation, autoimmune diseases, and neurodegenerative disorders, focusing on its lead compound, tegoprubart. This anti-CD40L antibody targets a key biological pathway, promising significant therapeutic potential.

Positive

• Scheduled financial results release for Q2 2022, indicating transparency.
• Focus on innovative treatments for organ and cell transplantation.

Negative

• None.

Management to host conference call and webcast at 4:30 pm ET

IRVINE, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced that it plans to release financial results for the second quarter ended June 30, 2022 on Thursday, August 11, after the close of trading. Eledon’s management team will host a conference call and webcast beginning at 4:30 p.m. ET.

Conference Call and Webcast Details:

Thursday, August 11, 2022 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time
Toll Free: 877-300-8521
International: 412-317-6026
Conference ID: 10169199
Webcast: https://ir.eledon.com/events-and-presentations/events

After the live webcast, the event will be archived on Eledon’s website for one year.

About Eledon Pharmaceuticals and tegoprubart (formerly AT-1501)

Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop potential treatments for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with ALS. The company’s lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential. Eledon is headquartered in Irvine, Calif. For more information, please visit the company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com

FAQ

When will Eledon Pharmaceuticals release its Q2 2022 financial results?

Eledon Pharmaceuticals will release its Q2 2022 financial results on August 11, 2022, after market close.

What time is the Eledon Pharmaceuticals conference call?

The conference call for Eledon Pharmaceuticals will take place at 4:30 p.m. ET on August 11, 2022.

What is the focus of Eledon Pharmaceuticals?

Eledon Pharmaceuticals focuses on developing treatments for organ transplantation, autoimmune conditions, and neurodegenerative diseases.

What is Eledon's lead compound?

Eledon's lead compound is tegoprubart, an anti-CD40L antibody aimed at targeting the CD40 Ligand pathway.